https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21794 9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]>